Calcitonin: Uses, Mechanism, and Reported Side Effects

Bone pain, high calcium levels, and postmenopausal bone loss are conditions people often want treated without more invasive options. Calcitonin is an older peptide therapy with a well-established regulatory history for several of these bone and calcium related conditions.

Key takeaways

• Calcitonin salmon is FDA-approved for Paget's disease of bone, hypercalcemia, and postmenopausal osteoporosis in select patients.
• It works as a calcitonin receptor agonist, acting mainly on bone with additional effects on the kidney and gut.
• Fracture reduction has not been demonstrated for the osteoporosis indication.
• The most commonly reported adverse events include nausea, drug ineffectiveness, falls, and various types of pain.
• More than 460 registered clinical trials reference calcitonin or related biomarkers.

What Calcitonin Is

Calcitonin salmon is a synthetic peptide classified under the pharmacologic class calcitonin. It acts as a calcitonin receptor agonist, meaning it binds to and activates the same receptors that the body's natural calcitonin uses. Its primary site of action is bone, though it also has recognized direct effects on the kidneys and gastrointestinal tract. Compared with mammalian calcitonins, the salmon-derived form is described as more potent per milligram and longer acting.

What Calcitonin Is Approved For

Calcitonin salmon injection, marketed as CALCITONIN SALMON, carries three approved indications. It is used to treat symptomatic Paget's disease of bone in patients with moderate to severe disease when alternative treatments are not suitable. It is also indicated for the treatment of hypercalcemia. The third approved use is postmenopausal osteoporosis, again when alternative treatments are not suitable, though the label notes that fracture reduction efficacy has not been demonstrated for this use. Because of a possible association between malignancy and calcitonin salmon use, prescribers are advised to periodically reevaluate the need for continued therapy. The label does not carry a boxed warning.

What the Evidence Shows

More than 460 clinical trials are registered that involve calcitonin or closely related biomarkers. Among the sampled studies, a completed Phase 1 trial examined extragonadal effects on calcium homeostasis. A separate trial exploring procalcitonin-guided antibiotic therapy in ICU sepsis patients was withdrawn before completion, and another study on biomarkers in idiopathic intracranial hypertension has an unknown status.

Reported Side Effects

Adverse event reports submitted to FAERS reflect reported associations, not confirmed incidence or causation. The most frequently reported reaction is nausea, followed closely by reports of the drug being ineffective. Falls, general pain, arthralgia, dizziness, headache, and back pain round out the most commonly reported terms, suggesting a pattern touching both gastrointestinal comfort and musculoskeletal or neurological symptoms.